Modeling the survival impact of the Inflation Reduction Act out-of-pocket cap in multiple myeloma

Clicks: 13
ID: 333674
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #384 of 407 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 407 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Oral immunomodulatory imide drugs (IMiDs) have become standard of care for newly diagnosed multiple myeloma (NDMM), but high out-of-pocket (OOP) costs may hinder treatment adherence. In 2025, the Inflation Reduction Act introduced a $2,000 annual OOP cost cap (IRAOOPcap) for Medicare Part D beneficiaries. In the absence of post-implementation data, we used comparative modeling to predict its survival impact. Methods The survival submodels of two independent Cancer Intervention and Surveillance Modeling Network (CISNET) natural history of multiple myeloma models were used. The models were parameterized using data from Surveillance, Epidemiology, and End Results (SEER)-Medicare, 2012–2021. We simulated survival among Medicare Part D beneficiaries with NDMM aged 66–75 and ≥76 years, under hypothetical scenarios shifting 0% (pre-IRAOOPcap) to 100% (best-case) of patients to IMiD use with high adherence and a realistic scenario using published data. We computed life-years gained (LYG) by comparing life expectancy (LE) under each scenario with that of the pre-IRAOOPcap scenario. Results Across models, the realistic/best-case scenario yielded LYG of 0.17–0.18/1.10–1.35 among patients aged 66–75 years, and 0.20–0.26/1.29–1.53 for those aged ≥76 years. These translated into 4,164–5,005/26,893–32,347 LYG at the population level for beneficiaries with NDMM in 2025. Conclusion The IRAOOPcap may improve survival through increasing IMiD utilization and adherence among Medicare Part D beneficiaries with NDMM. The projected gains represent a meaningful proportion of contemporary survival for patients. Future research should validate these gains when real-world data are available and inform future policy adaptation and extension.
Reference Key
openalex_W7223334989 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors H Zhao, Stanley Teng, Cynthia Dong, Ziyun Meng, Qingyuan Tan, Rong Wang, Mengmeng Ji, Martin William Schoen, Kristen Marie Sanfilippo, Mark Aaron Fiala, Shi-Yi Wang, Su-hsin Chang
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag396
URL
https://doi.org/10.1093/jnci/djag396
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.